Additional file 1 of A genetic map of the chromatin regulators to drug response in cancer cells

Additional file 1: Fig. S1. Lung cancer cell lines with RB1 mutations are resistant to CDK4/6 inhibitor, Fig. S2. Sensitive biomarkers interacted with CHEK1 in large intestine cancer cell lines, Fig. S3. Resistant biomarkers interacted with CHEK1 in lung cancer cell lines, Fig. S4. Functional analysis of the CRs genetic interaction, Fig. S5. Differential chromatin accessibility for CSL interactions, Fig. S6. Differential chromatin accessibility for CSV interactions, Fig. S7. TUBA1C subnetwork in drug related CSL network, Fig. S8. CRs genetic interactions were related to the prognosis of patients, Fig. S9. MAP2 CSL module mediate poor prognosis in COAD, Fig. S10. Vorinostat CSV module induces multiple omics deregulation in COAD, Fig. S11. SMARCA4 mutation was sensitive to FLT1 inhibitor in ovarian cancer cell lines, Fig. S12. The correlation between protein expression of mutated genes and the target genes dependency in lung cancer cell lines, Fig. S13. Comparison of the multi-mutation types conferred to CSL in the functional screen datasets, Fig. S14. Comparison of the multi-mutation types conferred to CSV in the functional screens datasets. Table S1. Functional screen datasets, Table S2. Pharmacogenomics datasets